Literature DB >> 2649244

Intratumour factors influencing the access of antibody to tumour cells.

L M Cobb1.   

Abstract

The histological structure and biochemical composition of human tumours is very varied, as is the structure of the microvascular network. It can be expected, therefore, that the extravasation, diffusion and convection of macromolecules will vary between tumours - and also between areas in the same tumour. The major factors influencing the intratumour distribution of injected antibody are reviewed and an attempt made to identify the tumour types in which therapeutic antibody, with or without a cytotoxin, will distribute most effectively.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649244     DOI: 10.1007/bf00205231

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  66 in total

1.  Increased tumor tissue pressure in association with the growth of rat tumors.

Authors:  K Hori; M Suzuki; I Abe; S Saito
Journal:  Jpn J Cancer Res       Date:  1986-01

2.  Endothelial fenestrations and other vascular alterations in primary melanoma of the central nervous system.

Authors:  J D Ward; M G Hadfield; D P Becker; E T Lovings
Journal:  Cancer       Date:  1974-12       Impact factor: 6.860

3.  Use of limitations of radiolabeled anti-CEA antibodies and their fragments for photoscanning detection of human colorectal carcinomas.

Authors:  J P Mach; M Forni; J Ritschard; F Buchegger; S Carrel; S Widgren; A Donath; P Alberto
Journal:  Oncodev Biol Med       Date:  1980-08

4.  Interstitial fluid pressure in DMBA-induced rat mammary tumours.

Authors:  H Wiig; E Tveit; R Hultborn; R K Reed; L Weiss
Journal:  Scand J Clin Lab Invest       Date:  1982-04       Impact factor: 1.713

5.  Improved radioimaging and tumor localization with monoclonal F(ab')2.

Authors:  R L Wahl; C W Parker; G W Philpott
Journal:  J Nucl Med       Date:  1983-04       Impact factor: 10.057

6.  Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.

Authors:  S E Order; G B Stillwagon; J L Klein; P K Leichner; S S Siegelman; E K Fishman; D S Ettinger; T Haulk; K Kopher; K Finney
Journal:  J Clin Oncol       Date:  1985-12       Impact factor: 44.544

7.  Biochemical studies of the matrix of craniovertebral chordoma and a metastasis.

Authors:  M B Sweet; E J Thonar; S D Berson; M I Skikne; A R Immelman; W A Kerr
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

8.  Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

Authors:  P D Senter; M G Saulnier; G J Schreiber; D L Hirschberg; J P Brown; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis.

Authors:  W H McBride; J B Bard
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

10.  Permeability of intestinal capillaries. Pathway followed by dextrans and glycogens.

Authors:  N Simionescu; M Simionescu; G E Palade
Journal:  J Cell Biol       Date:  1972-05       Impact factor: 10.539

View more
  13 in total

1.  Diffusion of an anti-transferrin receptor antibody in cultured murine melanoma cell layers.

Authors:  V Vijaykumar; E M Topp
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

2.  Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragments.

Authors:  A Chetanneau; R P Baum; P A Lehur; J C Liehn; A C Perkins; R Bares; P Bourguet; J Y Herry; J C Saccavini; J F Chatal
Journal:  Eur J Nucl Med       Date:  1990

3.  Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues.

Authors:  B Ballou; R Jaffe; S Persiani; W C Shen; J J Langone; H Sands; J M Reilandu; J Curley; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors.

Authors:  J Quak; G van Dongen
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

5.  Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984.

Authors:  A H Schrijvers; M Gerretsen; M van Walsum; B J Braakhuis; J J Quak; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Monoclonal antibody accumulation in experimental and spontaneous lung metastases of human malignant melanoma in rodents.

Authors:  U Schmid; M Bailly; O Fodstad; H Bihl; S Matzku
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma.

Authors:  H Bier; K A Reiffen; I Haas; P Stasiecki
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

8.  Monoclonal antibodies for the treatment of metastases. Evaluation of strategies using a syngeneic rat model.

Authors:  S A Eccles; G Box; W Court; M K Collins; C J Dean
Journal:  Cell Biophys       Date:  1993 Jan-Jun

9.  Radioimmunotargeting of human tumour cells in immunocompetent animals.

Authors:  J G Fjeld; O S Bruland; H B Benestad; L Schjerven; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

10.  Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.

Authors:  G M Boxer; R H Begent; A M Kelly; P J Southall; S B Blair; N A Theodorou; P M Dawson; J A Ledermann
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.